CEO transition positions Medifacts for growth and expansion
ROCKVILLE, MARYLAND (USA) / LANGENFELD, GERMANY– October 31, 2006 – Medifacts International, a global provider of clinical research and cardiac safety services, announced today that Michael E. Woehler, PhD has been named as the Company's new President and Chief Executive Officer.
Dr. Woehler has had more than 25 years of experience in leading global businesses in the life sciences and CRO industries. Most recently, he served as the Executive Vice President of PAREXEL International Corporation where he was responsible for the Worldwide Consulting, Medical Marketing Services and Clinical Pharmacology business, Corporate Services, and the Corporate Quality divisions. Dr. Woehler also served as PAREXEL's Senior Vice President and President of Clinical Research Services for four years where he managed 3000 employees worldwide.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.